Brunel University Research Archive(BURA) preserves and enables easy and open access to all
types of digital content. It showcases Brunel's research outputs.
Research contained within BURA is open access, although some publications may be subject
to publisher imposed embargoes. All awarded PhD theses are also archived on BURA.
Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/27373Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Gadar, K | - |
| dc.contributor.author | McCarthy, RR | - |
| dc.date.accessioned | 2023-10-12T10:42:02Z | - |
| dc.date.available | 2023-10-12T10:42:02Z | - |
| dc.date.issued | 2023-09-22 | - |
| dc.identifier | ORCID iD: Ronan R McCarthy https://orcid.org/0000-0002-7480-6352 | - |
| dc.identifier | 11 | - |
| dc.identifier.citation | Gadar, K. and McCarthy, R. (2023) 'Using next generation antimicrobials to target the mechanisms of infection', npj Antimicrobials and Resistance, 1 (1), pp. 1 - 14. doi: 10.1038/s44259-023-00011-6. | en_US |
| dc.identifier.uri | https://bura.brunel.ac.uk/handle/2438/27373 | - |
| dc.description | Competing interests: Brunel University London has priority patent fillings covering the therapeutic use of artificial sweeteners. | - |
| dc.description.abstract | Copyright © The Author(s) 2023. The remarkable impact of antibiotics on human health is being eroded at an alarming rate by the emergence of multidrug resistant pathogens. There is a recognised consensus that new strategies to tackle infection are urgently needed to limit the devasting impact of antibiotic resistance on our global healthcare infrastructure. Next generation antimicrobials (NGAs) are compounds that target bacterial virulence factors to disrupt pathogenic potential without impacting bacterial viability. By disabling the key virulence factors required to establish and maintain infection, NGAs make pathogens more vulnerable to clearance by the immune system and can potentially render them more susceptible to traditional antibiotics. In this review, we discuss the developing field of NGAs and how advancements in this area could offer a viable standalone alternative to traditional antibiotics or an effective means to prolong antibiotic efficacy when used in combination. | en_US |
| dc.description.sponsorship | RRMC is supported by a Biotechnology and Biological Sciences Research Council New Investigator Award BB/V007823/1and NERC NE/X010902/1. RRMC is also supported by the Academy of Medical Sciences/the Wellcome Trust/the Government Department of Business, Energy and Industrial Strategy/the British Heart Foundation/Diabetes UK Springboard Award [SBF006\1040]. | en_US |
| dc.format.extent | 1 - 14 | - |
| dc.format.medium | Electronic | - |
| dc.language | English | - |
| dc.language.iso | en | en_US |
| dc.publisher | Springer Nature | en_US |
| dc.rights | Copyright © The Author(s) 2023. Rights and permissions: Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. | - |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
| dc.title | Using next generation antimicrobials to target the mechanisms of infection | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | https://doi.org/10.1038/s44259-023-00011-6 | - |
| dc.relation.isPartOf | npj Antimicrobials and Resistance | - |
| pubs.issue | 1 | - |
| pubs.publication-status | Published online | - |
| pubs.volume | 1 | - |
| dc.identifier.eissn | 2731-8745 | - |
| dc.rights.holder | The Author(s) | - |
| Appears in Collections: | Dept of Life Sciences Research Papers | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| FullText.pdf | Copyright © The Author(s) 2023. Rights and permissions: Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. | 1.01 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License
